Product Information
C8 Galactosylceramide boosts doxorubicin efficacy in cancer cells, not healthy ones, and affects splenocyte growth and cytokine release at 100-1,000 ng/ml.
Chemical properties
Technical inquiry about: TM-T36323 C8 Galactosylceramide (d18:1/8:0)
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.